/
GRAL
$65.81+$1.48 (+2.25%)live
Held · Bookmarked
1 · 0
portfolio · users
Avg position size
0.0%
of holders' portfolios
13F filers
1
institution
Market cap
$2.8B
43M shares
52-week range
$29.95 – $118.84
40% from low
Sector
SERVICES-MEDICAL LABORATORIES
Exchange
NASDAQ
CS
Borrow rate
0.40%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$50.40
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $14.6M | $55.5M | $93.1M | $125.6M | $147.2M |
| Cost of revenue | $0 | $0 | $0 | $114.6M | $172.0M | $188.7M | $203.6M | $209.7M |
| Gross profit | $0 | $0 | $0 | −$100.0M | −$116.4M | −$95.6M | −$78.0M | −$62.6M |
| Gross margin | — | — | — | -684.4% | -209.6% | -102.7% | -62.1% | -42.5% |
| R&D | $223.2M | $167.1M | $192.9M | $460.2M | $329.6M | $338.7M | $322.4M | $195.8M |
| Operating income | −$287.5M | −$255.7M | −$316.4M | −$1.27B | −$5.44B | −$1.52B | −$2.19B | −$534.2M |
| EBITDA | −$269.4M | −$243.1M | −$308.7M | −$1.21B | −$587.7M | −$638.2M | −$610.2M | −$378.2M |
| Net income | −$275.7M | −$244.9M | −$312.2M | −$1.25B | −$5.40B | −$1.47B | −$2.03B | −$408.4M |
| Net margin | — | — | — | -8539.4% | -9719.3% | -1574.2% | -1613.9% | -277.5% |
| EPS (diluted) | -2.42 | -1.99 | -2.52 | -40.18 | -173.87 | -47.20 | -63.54 | -11.11 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $179M | $-10.33 | $-10.46–$-10.17 | 5 |
| 2027 | $223M | $-10.62 | $-11.01–$-10.17 | 5 |
| 2028 | $286M | $-10.07 | $-13.33–$-7.95 | 8 |
| 2029 | $378M | $-10.57 | $-11.67–$-9.66 | 6 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
GRAIL, Inc. Common Stock
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.
www.grail.com- Employees
- 910
- IPO / List date
- Jun 12, 2024
- HQ
- MENLO PARK, CA
Held by traders on TradeandTell
| Trader / Portfolio | Conviction |
|---|---|
| RH IndividualLiam | — |
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 55,200 | $2.9M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
- 6/28/2026in RH Individual →
